NCT05956041View on ClinicalTrials.gov

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Cutaneous T Cell LymphomaFungoides Mycosis Sezary Syndrome
Interventions
DRUG

Pembrolizumab

400mg Intravenously

DRUG

Mogamulizumab

1mg/kg Intravenously

Trial Locations (1)

48109

RECRUITING

University of Michigan Comprehensive Cancer Center, Ann Arbor

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Hoosier Cancer Research Network

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER